Research ArticleArticle
Failure in Longterm Treatment is Rare in Actively Treated Patients with Rheumatoid Arthritis, But May Be Predicted by High Health Assessment Score at Baseline and by Residual Disease Activity at 3 and 6 Months: The 5-year Followup Results of the Randomized Clinical NEO-RACo Trial
Vappu Rantalaiho, Hannu Kautiainen, Salme Järvenpää, Markku Korpela, Timo Malmi, Pekka Hannonen, Oili Kaipiainen-Seppänen, Timo Yli-Kerttula, Timo Möttönen, Anu Mustila, Anna Karjalainen, Leena Paimela, Toini Uutela and Marjatta Leirisalo-Repo
The Journal of Rheumatology October 2014, jrheum.140267; DOI: https://doi.org/10.3899/jrheum.140267
Vappu Rantalaiho
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Hannu Kautiainen
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Salme Järvenpää
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Markku Korpela
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Timo Malmi
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Pekka Hannonen
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Oili Kaipiainen-Seppänen
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Timo Yli-Kerttula
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Timo Möttönen
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Anu Mustila
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Anna Karjalainen
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Leena Paimela
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Toini Uutela
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Marjatta Leirisalo-Repo
From the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; Fimlab Laboratories, Tampere; Unit of Primary Health Care; Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital; Department of General Practice; Institute of Clinical Medicine, University of Helsinki; Orton Hospital, Helsinki; Unit of Primary Health Care; Department of Medicine, Kuopio University Hospital, Kuopio; Medcare Foundation, Äänekoski; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Medicine, Jyväskylä Central Hospital, Jyväskylä; Department of Rheumatology, Satakunta Central Hospital, Rauma; Division of Medicine and Department of Rheumatology, Turku University Hospital, Turku; Department of Medicine, Oulu University Hospital, Oulu; Central Hospital of Lapland, Rovaniemi, Finland. Supported by the Competitive Research Funding of the Tampere University Hospital (Grants 9M124 and 9M128), the Helsinki University Central Hospital Research Funds, and Finska Läkaresällskapet. V. Rantalaiho has received a personal grant from the Orion-Farmos Research Foundation. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. V. Rantalaiho, MD, PhD, Docent, Specialist in Rheumatology in the Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; H. Kautiainen, Professor of Biostatistics, Unit of Primary Health Care, Helsinki University Central Hospital, Department of General Practice, University of Helsinki, Unit of Primary Health Care, Kuopio University Hospital; S. Järvenpää, Biostatistician, Medcare Foundation; M. Korpela, MD, PhD, Docent, Chief of Division, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; T. Malmi, MD, Specialist in Rheumatology, Department of Medicine, Seinäjoki Central Hospital; P. Hannonen, MD, PhD, Professor, Head of Department, Department of Medicine, Jyväskylä Central Hospital; O. Kaipiainen-Seppänen, MD, PhD, Docent, Chief of Division, Department of Medicine, Kuopio University Hospital; T. Yli-Kerttula, MD, PhD, Chief of Division, Department of Rheumatology, Satakunta Central Hospital; T. Möttönen, MD, PhD, Professor, Chief of Division, Division of Medicine, Department of Rheumatology, Turku University Hospital; A. Mustila, MD, PhD, Head of Department, Fimlab Laboratories; A. Karjalainen, MD, PhD, Assistant Chief of Division, Department of Medicine, Oulu University Hospital; L. Paimela, MD, PhD, Rheumatology Consultant, Orton Hospital; T. Uutela, MD, Head of Department, Central Hospital of Lapland; M. Leirisalo-Repo, MD, PhD, Professor, Chief of Division, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki. Address correspondence to Dr. V. Rantalaiho, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI-33521 Tampere, Finland. E-mail: vappu.rantalaiho@pshp.fi. Accepted for publication August 1, 2014.
Roles: for the NEO-RACo Study Group
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Failure in Longterm Treatment is Rare in Actively Treated Patients with Rheumatoid Arthritis, But May Be Predicted by High Health Assessment Score at Baseline and by Residual Disease Activity at 3 and 6 Months: The 5-year Followup Results of the Randomized Clinical NEO-RACo Trial
Vappu Rantalaiho, Hannu Kautiainen, Salme Järvenpää, Markku Korpela, Timo Malmi, Pekka Hannonen, Oili Kaipiainen-Seppänen, Timo Yli-Kerttula, Timo Möttönen, Anu Mustila, Anna Karjalainen, Leena Paimela, Toini Uutela, Marjatta Leirisalo-Repo
The Journal of Rheumatology Oct 2014, jrheum.140267; DOI: 10.3899/jrheum.140267
Failure in Longterm Treatment is Rare in Actively Treated Patients with Rheumatoid Arthritis, But May Be Predicted by High Health Assessment Score at Baseline and by Residual Disease Activity at 3 and 6 Months: The 5-year Followup Results of the Randomized Clinical NEO-RACo Trial
Vappu Rantalaiho, Hannu Kautiainen, Salme Järvenpää, Markku Korpela, Timo Malmi, Pekka Hannonen, Oili Kaipiainen-Seppänen, Timo Yli-Kerttula, Timo Möttönen, Anu Mustila, Anna Karjalainen, Leena Paimela, Toini Uutela, Marjatta Leirisalo-Repo
The Journal of Rheumatology Oct 2014, jrheum.140267; DOI: 10.3899/jrheum.140267